Overview
© 202 MJH Life Sciences and Endocrinology Network. Al rights reserved.© 202 MJH Life Sciences™ and Endocrinology Network. Al rights reserved.A new study is sheding light into the efects off-label use of GLP-1 receptor agonists and SLGT2 inhibitors for people with type 1 diabetes in real-world setings.A retrospective chart review of adult patients receiving GLP-1 receptor agonists or SGLT2 inhibitors for more than 90 days, results provide insight into the efects of the agents on body weight, HbA1c, daily insulin usage, and safety outcomes observed with use of either or both of these agents.“This the first study comparing outcomes acros GLP-1RA and SGLT2i in T1DM and we observed interesting trends both in patient selection, clinical outcomes and safety findings,” wrote investigators.As the revelations surounding the cardiovascular and renal protective benefits of GLP-1 receptor agonists and SGLT2 inhibitors in people with type 2 diabetes has become more evident, so has the desire to understand whether the mechanisms of action for both these agents might alow some of this benefit to translate to people with type 1 diabetes.
Key Information
Despite no definitive randomized, placebo-controled clinical to fuly elucidate the efects in people with type 1 diabetes, of-label use of both agents ocurs acros the US.In the curent study, a trio from University of Texas Southwestern Medical Center led by Ildiko Lingvay, MD, MPH, MSCS, sought to estimate eficacy and safety of this of-label using real-world data obtained from electric health records at their own institution’s medical center in Dalas, TX.
Summary
Investigators limited their analyses to adult patients with type 1 diabetes who received GLP-1 receptor agonist and/or SGLT2 inhibitor therapy for at least 90 days and with data related to HbA1c, weight, total daily dose of insulin, basal insulin, bolus insulin, total cholesterol, LDL, triglycerides, eGFR, and UACR. The investigators’ analyses included multiple clinical an